Community/Retail

Inhaled insulin Afrezza offers a rapid-acting alternative for children with type 1 diabetes, enhancing blood glucose control and patient satisfaction.

FDA approves Uzedy, an extended-release injectable formulation of risperidone, enhancing treatment options for adults with bipolar I disorder.

The pharmaceutical giant will reportedly lower its drug prices to align with most-favored-nation status.

Public debate intensifies as Robert F. Kennedy Jr compares selective serotonin reuptake inhibitors (SSRIs) to heroin, prompting mental health experts to clarify antidepressant use and withdrawal misconceptions.

A hybrid chatbot that evaluates stages of change in pneumococcal vaccination desires while providing artificial intelligence (AI)-based Q&A opportunities improved uptake in older adults.

The FDA approves Eydenzelt, a biosimilar for retinal diseases, enhancing treatment options for diabetic macular edema and age-related macular degeneration.

Researchers highlight the critical link between school vaccination rates and measles outbreaks, urging targeted public health strategies to combat misinformation and improve MMR coverage.

Discover groundbreaking FDA approvals for innovative treatments, including semaglutide for liver health and bumetanide nasal spray for heart failure.

Explore recent FDA-approved drugs from September 2025.

Research reveals that poor glycemic control in adolescents with type 1 diabetes significantly increases the risk of developing neuropathy in adulthood.

Tramadol provides only limited pain relief while carrying a significant risk of serious adverse effects.

Discover how supplements support women's health during menopause, enhancing well-being and easing symptoms effectively.

GLP-1 receptor agonists significantly influence FDG-PET-CT scan interpretations, potentially leading to misdiagnosis in cancer detection.

Many factors lead to policy change and market viability, but none more than perceived need and desire to receive a service.

As one of the most prescribed medications worldwide, proton pump inhibitor use could serve as a bulwark against severe outcomes in hospitalized adults with COVID-19.

Pharmaceutical companies navigate FDA regulations and explore AI solutions to enhance compliance in drug advertising and enforcement.

Researchers explore continuous glucose monitors (CGMs) for early detection of insulin issues, aiming to prevent diabetes progression and improve screening methods.

New research confirms that calcium supplements do not increase dementia risk in older women, supporting their use for bone health without cognitive concerns.

Christian Ruff, MD, highlights pharmacists as essential clinical partners who help optimize drug selection, dosing, and safety for patients with complex needs.

Cagrilintide shows significant weight loss in adults with obesity, marking a breakthrough in obesity treatment with promising phase 3 trial results.

Pharmacists’ accessibility and expertise make them essential allies for patients managing weight through medication, Donna Ryan explains.

Vaccination with 23-valent pneumococcal polysaccharide vaccine did not reduce the rates of acute coronary syndrome and ischemic stroke in a randomized clinical trial.

Craig Beavers discusses recent developments in hypertension management and the clinical implications of the Bax Hypertension and KARDIA-3 trials with Shelby Tungate from the UNC Eshelman School of Pharmacy.

Recent research confirms that rheumatoid arthritis patients in remission can safely switch to the biosimilar infliximab-dyyb, offering a cost-effective treatment option.

William Van Decker, MD, discusses the key priorities of the upcoming ACC Legislative Conference, including telehealth, cardiovascular rehab, prior authorization reform, and the role of pharmacists in shaping patient-centered cardiovascular policy.

Johnson & Johnson presented new long-term data of icotrokinra from ICONIC-LEAD, along with data from ICONIC-ADVANCE indicating head-to-head superiority with standard-of-care deucravacitinib.